Since TZT activates both GIP and GLP-1, it induces a remarkable reduction in body weight, unlike GIPR agonist, which is implicated in the development of obesity when used alone (Seino and Yamazaki 2022). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.